title: Bilateral diffuse uveal melanocytic proliferation with a positive ophthalmoscopic and visual response to plasmapheresis.
authors.forename: Rebecca B
authors.initials: RB
authors.lastname: Mets
authors.forename: Pamela
authors.initials: P
authors.lastname: Golchet
authors.forename: Grazyna
authors.initials: G
authors.lastname: Adamus
authors.forename: Roberto
authors.initials: R
authors.lastname: Anitori
authors.forename: David
authors.initials: D
authors.lastname: Wilson
authors.forename: John
authors.initials: J
authors.lastname: Shaw
authors.forename: Lee M
authors.initials: LM
authors.lastname: Jampol
mesh_terms: D000368:Aged; D001323:Autoantibodies / Q000097:blood; D001557:Benzenesulfonates / Q000627:therapeutic use; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy / Q000473:pathology; D049109:Cell Proliferation; D005136:Eye Proteins / Q000276:immunology; D017809:Fatal Outcome; D005451:Fluorescein Angiography; D007839:Functional Laterality; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008544:Melanocytes / Q000473:pathology*; D009536:Niacinamide / Q000031:analogs & derivatives; D009887:Ophthalmoscopy; D010257:Paraneoplastic Syndromes / Q000175:diagnosis* / Q000628:therapy; D010671:Phenylurea Compounds; D010956:Plasmapheresis; D011725:Pyridines / Q000627:therapeutic use; D012160:Retina / Q000276:immunology; D000077157:Sorafenib; D041623:Tomography, Optical Coherence; D014603:Uveal Diseases / Q000175:diagnosis* / Q000628:therapy; D014792:Visual Acuity / Q000502:physiology; D014794:Visual Fields
chemical_list: D001323:Autoantibodies; D001557:Benzenesulfonates; D005136:Eye Proteins; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib